ChiCTR2500104191 版本V1.0 版本创建时间2025/06/12 10:46:24 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500104191 

最近更新日期:

Date of Last Refreshed on:

2025-06-12 10:46:18 

注册时间:

Date of Registration:

2025-06-12 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

术前不同口服补液方案对胸腔镜肺癌根治术老年患者安全性、舒适性及术后转归的影响

Public title:

The impact of different oral rehydration regimens before surgery on the safety, comfort and postoperative

注册题目简写:

English Acronym:

研究课题的正式科学名称:

术前不同口服补液方案对胸腔镜肺癌根治术老年患者安全性、舒适性及术后转归的影响

Scientific title:

The impact of different oral rehydration regimens before surgery on the safety, comfort and postoperative

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

林楠 

研究负责人:

林楠 

Applicant:

Lin Nan 

Study leader:

Lin Nan 

申请注册联系人电话:

Applicant telephone:

+86 18518134145

研究负责人电话:

Study leader's telephone:

+86 18518134145

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

117806006@qq.com

研究负责人电子邮件:

Study leader's E-mail:

117806006@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

福建省福州市鼓楼区新权路29号

研究负责人通讯地址:

福建省福州市鼓楼区新权路29号

Applicant address:

No. 29, Xinquan Road, Gulou District, Fuzhou City, Fujian Province

Study leader's address:

No. 29, Xinquan Road, Gulou District, Fuzhou City, Fujian Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

福建医科大学附属协和医院

Applicant's institution:

Fujian Medical University Union Hospital

研究负责人所在单位:

福建医科大学附属协和医院

Affiliation of the Leader:

Fujian Medical University Union Hospital

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2025KY140

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

福建医科大学附属协和医院科研伦理委员会

Name of the ethic committee:

Fujian Medical University Union Hospital Research Ethics Committee

伦理委员会批准日期:

Date of approved by ethic committee:

2025-05-09 00:00:00

伦理委员会联系人:

阮文倩

Contact Name of the ethic committee:

Ruan Wenqian

伦理委员会联系地址:

福建省福州市鼓楼区新权路29号

Contact Address of the ethic committee:

No. 29, Xinquan Road, Gulou District, Fuzhou City, Fujian Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 591 86218340

伦理委员会联系人邮箱:

Contact email of the ethic committee:

xhyyllwyh@163.com

研究实施负责(组长)单位:

福建医科大学附属协和医院

Primary sponsor:

Fujian Medical University Union Hospital

研究实施负责(组长)单位地址:

福建省福州市鼓楼区新权路29号

Primary sponsor's address:

No. 29, Xinquan Road, Gulou District, Fuzhou City, Fujian Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

福建省

市(区县):

Country:

China

Province:

Fujian

City:

单位(医院):

福建医科大学附属协和医院

具体地址:

福建省福州市鼓楼区新权路29号

Institution
hospital:

Fujian Medical University Union Hospital

Address:

No. 29, Xinquan Road, Gulou District, Fuzhou City, Fujian Province

经费或物资来源:

自选课题(自筹)

Source(s) of funding:

Self-selected project (self-funded)

Target disease:

Postoperative delirium

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

本研究旨在对比新的术前口服补液方案(术前每小时口服50-100ml清液体或碳水化合物饮料直至接病人)和传统术前2小时口服200-300ml清水方案。通过研究,探究两种方案对胸腔镜肺癌根治术老年患者的安全性(如反流误吸风险)、舒适性(饥饿、口渴、焦虑程度)、胃排空状态(胃超声指标),以及术后转归(术后谵妄、胰岛素抵抗、炎症因子水平)的影响,为老年肺癌患者找到更合适的术前补液方案。  

Objectives of Study:

This study aims to compare the new preoperative oral rehydration protocol (administering 50–100 mL of clear fluids or carbohydrate-rich beverages orally every hour until the patient arrives at the operating room) with the traditional preoperative protocol (consuming 200–300 mL of water orally two hours prior to surgery). The objective is to investigate the effects of these two protocols on the safety (e.g., risk of reflux and aspiration), comfort (e.g., levels of hunger, thirst, and anxiety), gastric emptying status (as assessed by gastric ultrasound indicators), and postoperative outcomes (e.g., incidence of postoperative delirium, insulin resistance, and inflammatory factor levels) in elderly patients undergoing thoracoscopic lung cancer radical surgery. This research seeks to identify a more appropriate preoperative rehydration protocol for elderly lung cancer patients.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.年龄>=65岁,拟行胸腔镜肺癌根治术的老年患者; 2.美国麻醉医师协会(ASA)分级 Ⅱ-Ⅲ 级; 3.无严重认知功能障碍(简易精神状态量表MMSE评分>=24分); 4.能够配合研究,签署知情同意书;

Inclusion criteria

1. Elderly patients aged >=65 years old who intend to undergo thoracoscopic radical lung cancer resection; 2. American Society of Anesthesiologists (ASA) grade II.-III.; 3. No severe cognitive impairment (Mini-Mental State Scale MMSE score >=24 points); 4. Able to cooperate with the study and sign the informed consent form;

排除标准:

1.合并严重心、肝、肾等重要脏器功能障碍。 2.患有糖尿病、甲状腺功能亢进等代谢性疾病。 3.存在胃排空障碍、吞咽困难、肠梗阻等消化系统疾病。 4.对碳水化合物过敏或不耐受。 5.术前已接受放化疗等可能影响研究指标的治疗。 6.精神疾病或认知功能障碍患者。

Exclusion criteria:

1. Combined with severe dysfunction of important organs such as heart, liver, and kidney. 2. Suffering from metabolic diseases such as diabetes mellitus and hyperthyroidism. 3. Digestive system diseases such as gastric emptying disorders, dysphagia, and intestinal obstruction. 4. Allergy or intolerance to carbohydrates. 5. Have received radiotherapy and chemotherapy and other treatments that may affect the research indicators before surgery. 6. Patients with mental illness or cognitive dysfunction.

研究实施时间:

Study execute time:

From 2025-06-15 00:00:00 To 2026-04-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-06-15 00:00:00 To 2026-01-01 00:00:00  

干预措施:

Interventions:

组别:

干预组2

样本量:

140

Group:

Intervention group 2

Sample size:

干预措施:

术前每小时口服50-100ml含12.5%碳水化合物的饮料

干预措施代码:

Intervention:

The intervention group 2 was orally given 50 - 100 ml of a beverage containing

Intervention code:

组别:

干预组1

样本量:

140

Group:

Intervention group 1

Sample size:

干预措施:

术前每小时口服50-100ml清水;

干预措施代码:

Intervention:

The intervention group 1 was orally given 50 - 100 ml of water every hour before the operation;

Intervention code:

组别:

对照组

样本量:

140

Group:

The control group

Sample size:

干预措施:

术前2小时口服200 - 300ml清水

干预措施代码:

Intervention:

The control group was prohibited from eating solid food 6 hours before the operation, and was orally given 200 - 300 ml of water 2 hours before the op

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

福建省 

市(区县):

 

Country:

China 

Province:

Fujian 

City:

 

单位(医院):

福建医科大学附属协和医院 

单位级别:

三级甲等 

Institution
hospital:

Fujian Medical University Union Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

术后谵妄发生率

指标类型:

主要指标

Outcome:

The incidence of postoperative delirium

Type:

Primary indicator

测量时间点:

术后一到三天

测量方法:

CAM术后谵妄评估量表

Measure time point of outcome:

One to three days after the operation

Measure method:

CAM Postoperative Delirium Assessment Scale

指标中文名:

围术期饥饿感

指标类型:

次要指标

Outcome:

Perioperative hunger

Type:

Secondary indicator

测量时间点:

分别于术前 2 小时、术前 1 小时、进入手术室前及术后6小时

测量方法:

视觉模拟评分法(VAS),让患者对饥饿感(0-10 分,0 为无饥饿感,10 为极度饥饿)、口渴感(0-10 分,0 为无口渴感,10 为极度口渴)进行评分

Measure time point of outcome:

2 hours and 1 hour before the operation, before anesthesia induction and 6 hours after the operation

Measure method:

The Visual Analogue Scale (VAS) allowed patients to rate their feelings of hunger (0-10 points, 0 for no hunger and 10 for extreme hunger) and thirst (0-10 points, 0 for no thirst and 10 for extreme thirst)

指标中文名:

C反应蛋白(CRP)

指标类型:

次要指标

Outcome:

C-reactive protein

Type:

Secondary indicator

测量时间点:

分别于术前 1 天清晨、术后第 1 天清晨、术后第 3 天清晨

测量方法:

采集患者空腹静脉血采用免疫比浊法检测

Measure time point of outcome:

On the early morning of the day before the operation,the first day and the third day after operation

Measure method:

The fasting venous blood of the patients was collected and detected by immunoturbidimetry.

指标中文名:

围术期恶心呕吐发生率

指标类型:

次要指标

Outcome:

The incidence of perioperative nausea and vomiting

Type:

Secondary indicator

测量时间点:

术中及术后3天

测量方法:

记录恶心呕吐发生次数和严重程度

Measure time point of outcome:

During the operation and 3 days after the operation

Measure method:

Record the frequency and severity of nausea and vomiting

指标中文名:

肿瘤坏死因子-α(TNF-α)

指标类型:

次要指标

Outcome:

Tumor necrosis factor -α

Type:

Secondary indicator

测量时间点:

分别于术前 1 天清晨、术后第 1 天清晨、术后第 3 天清晨

测量方法:

采集患者空腹静脉血采用酶联免疫吸附试验(ELISA)检测

Measure time point of outcome:

On the early morning of the day before the operation,the first day and the third day after operation

Measure method:

The fasting venous blood of the patients was collected and detected by enzyme-linked immunosorbent assay (ELISA).

指标中文名:

围术期反流误吸发生率

指标类型:

次要指标

Outcome:

The incidence of reflux aspiration during the perioperative period

Type:

Secondary indicator

测量时间点:

术中及术后3天

测量方法:

密切观察患者是否出现反流、误吸的情况

Measure time point of outcome:

During the operation and 3 days after the operation

Measure method:

Closely observe whether the patient has reflux or aspiration

指标中文名:

胃内残余液体量

指标类型:

主要指标

Outcome:

The amount of fluid in the stomach

Type:

Primary indicator

测量时间点:

术前 2 小时、术前 1 小时、麻醉诱导前

测量方法:

超声检查胃窦横截面积

Measure time point of outcome:

2 hours before the operation, 1 hour before the operation, and before anesthesia induction

Measure method:

Ultrasound examination of the cross-sectional area of the antrum of the stomach

指标中文名:

胰岛素抵抗

指标类型:

主要指标

Outcome:

insulin resistance

Type:

Primary indicator

测量时间点:

分别于术前 1 天清晨、术后第 1 天清晨、术后第 3 天清晨

测量方法:

采集患者空腹静脉血检测空腹血糖(FPG)、胰岛素(FINS)、稳态模型胰岛素抵抗指数(HOMA-IR)

Measure time point of outcome:

On the early morning of the day before the operation,the first day and the third day after operation

Measure method:

Fasting venous blood was collected from the patients to detect fasting plasma glucose (FPG), insulin (FINS), and homeostasis model assessment of insulin resistance index (HOMA-IR).

指标中文名:

白细胞介素-6(IL-6)

指标类型:

次要指标

Outcome:

Interleukin-6

Type:

Secondary indicator

测量时间点:

分别于术前 1 天清晨、术后第 1 天清晨、术后第 3 天清晨

测量方法:

采集患者空腹静脉血采用酶联免疫吸附试验(ELISA)检测

Measure time point of outcome:

On the early morning of the day before the operation,the first day and the third day after operation

Measure method:

The fasting venous blood of the patients was collected and detected by enzyme-linked immunosorbent assay (ELISA).

指标中文名:

术前焦虑

指标类型:

主要指标

Outcome:

preoperative anxiety

Type:

Primary indicator

测量时间点:

术前 1 天和术晨

测量方法:

焦虑自评量表(SAS)

Measure time point of outcome:

One day before the operation and in the morning of the operation

Measure method:

Self-rating Anxiety Scale (SAS)

指标中文名:

围术期口渴感

指标类型:

次要指标

Outcome:

Perioperative thirst

Type:

Secondary indicator

测量时间点:

分别于术前 2 小时、术前 1 小时、麻醉诱导前及术后6小时

测量方法:

视觉模拟评分法(VAS),口渴感(0-10 分,0 为无口渴感,10 为极度口渴)进行评分

Measure time point of outcome:

2 hours and 1 hour before the operation, before anesthesia induction and 6 hours after the operation

Measure method:

The Visual Analogue Scale (VAS) was used to score the sensation of thirst (on a scale of 0 to 10, where 0 indicates no sensation of thirst and 10 indicates extreme thirst)

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后保存  

说明

Fate of sample:

Preservation after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 65 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

统计人员根据研究设计确定分组数量(对照组、干预组 1、干预组 2 共 3 组),在使用SAS计算机软件中设定随机化参数,生成符合研究样本量(420 例)的随机数字序列,并将每个数字对应分配至不同组别。随机序列生成后,以加密电子文档形式封存,直至数据收集完成且盲态审核通过前,研究团队任何成员均无权查阅。

Randomization Procedure (please state who generates the random number sequence and by what method):

The statisticians determined the number of groups (a total of 3 groups, namely the control group, intervention group 1, and intervention group 2) based on the research design. They set the randomization parameters using the SAS computer software, generated random number sequences that corresponded to the study sample size (420 cases), and assigned each number to different groups accordingly. After the random sequence is generated, it is sealed in the form of an encrypted electronic document. Until the data collection is completed and the blind review is passed, no member of the research team has the right to access it.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

双盲,对研究参与者和研究者设盲

Blinding:

Double-blind, blinding the study participants and investigators

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

研究结束后,通过ResMan(www.medresman.org.cn)方式共享

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

After the end of the study, it was shared by ResMan (www.medresman.org.cn).

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF;EDC

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF;EDC

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2025-06-12 10:46:18